Phase II Multicenter Clinical Trial on Imatinib Treatment for Patients With Resectable Hepatic Metastasis From Gastrointestinal Stromal Tumors (GISTs)
- To evaluate the safety and efficacy of imatinib mesylate in patients with resectable
hepatic metastasis secondary to gastrointestinal stromal tumor.
OUTLINE: This is a multicenter study.
Patients receive oral imatinib mesylate daily. Treatment continues in the absence of disease
progression or unacceptable toxicity.
Masking: Open Label, Primary Purpose: Treatment
Tatsuo Kanda, MD
Niigata University Medical and Dental Hospital
United States: Federal Government